Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 578.64 | 500.56 | 512.69 | 394.92 | 368.59 |
Total Expenses | 547.86 | 510.25 | 507.93 | 407.33 | 386.56 |
Profit Before Tax | 56.34 | -10.29 | 81.13 | -12.41 | 64.67 |
Profit After Tax | 55.96 | -10.40 | 81.47 | -12.61 | 64.46 |
Operating Profit after Depreciation | 59.96 | 11.70 | 25.37 | 10.67 | 14.90 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 166.82 | 167.11 | 167.11 | 167.38 | 163.90 |
Total Non Current Assets | 184.21 | 181.71 | 181.31 | 191.65 | 188.79 |
Total Current Assets | 159.29 | 121.81 | 171.24 | 97.53 | 89.90 |
TOTAL ASSETS | 343.49 | 303.52 | 352.55 | 289.18 | 278.69 |
Total Shareholder's Fund | 27.94 | -32.82 | -23.42 | -156.24 | -143.45 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 3.98 | 19.80 | 40.52 | 16.68 | 44.13 |
Net Cash used in Investing Activities | -16.63 | -8.84 | 0.59 | 8.04 | 63.66 |
Net Cash used in Financing Activities | 14.55 | -31.99 | -28.58 | -17.39 | -107.87 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 578.64 | 500.56 | 512.69 | 394.92 | 368.59 |
Total Expenses | 547.86 | 510.25 | 507.93 | 407.33 | 386.56 |
Profit Before Tax | 30.78 | -10.29 | 81.13 | -12.41 | 64.67 |
Profit After Tax | 30.40 | -10.40 | 81.47 | -12.61 | 64.46 |
Operating Profit after Depreciation | 59.96 | 11.70 | 25.37 | 10.67 | 14.90 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 166.82 | 167.11 | 167.11 | 167.38 | 163.90 |
Total Non Current Assets | 184.21 | 181.71 | 181.31 | 191.65 | 188.79 |
Total Current Assets | 159.29 | 120.19 | 169.69 | 95.95 | 88.37 |
TOTAL ASSETS | 343.49 | 301.90 | 351 | 287.60 | 277.16 |
Total Shareholder's Fund | 27.94 | -7.26 | 2.19 | -130.66 | -117.83 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 4.02 | 19.80 | 40.52 | 16.68 | 44.13 |
Net Cash used in Investing Activities | -16.63 | -8.84 | 0.59 | 8.04 | 63.66 |
Net Cash used in Financing Activities | 14.55 | -31.99 | -28.58 | -17.39 | -107.87 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 161.19 | 131.11 | 139.41 | 145.50 | 144.46 |
Total Expenses | 141.19 | 120.13 | 121.24 | 124.35 | 127.12 |
Profit Before Tax | 8.16 | 1.04 | 33.92 | 10.26 | 7.19 |
Profit After Tax | 8.02 | 1.04 | 33.63 | 10.27 | 7.36 |
Operating Profit after Depreciation | 21.63 | 11.92 | 19.10 | 21.84 | 18.10 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 161.19 | 131.11 | 139.41 | 145.50 | 144.46 |
Total Expenses | 141.19 | 120.13 | 121.24 | 124.35 | 127.12 |
Profit Before Tax | 8.16 | 1.04 | 8.36 | 10.26 | 7.19 |
Profit After Tax | 8.02 | 1.04 | 8.08 | 10.27 | 7.36 |
Operating Profit after Depreciation | 21.63 | 11.92 | 19.10 | 21.84 | 18.10 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Wanbury Ltd | ₹226.25 | ₹741.43 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
09 Jan 2025, 10:32 am
06 Nov 2024, 11:06 am
11 Sep 2024, 09:18 am
08 Aug 2024, 05:17 pm
28 Jun 2024, 09:41 am